#ESMO26 VOLGA (phase III, N=695): MIBC patients ineligible for or declining cisplatin. Perioperative durvalumab + neoadjuvant enfortumab vedotin vs radical cystectomy ± adjuvant therapy: 2-year EFS 64% vs 45% (HR 0.51); 2-year OS 78% vs 69% (HR 0.58; 95% CI: 0.40-0.83; p=0.0027).
6 views · 0 likes · 0 reposts · 0 replies
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDarolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.orgSource: Rafał Bogdan Drobot · x.com